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Dr Francis C. Nichols (Rochester, Minnesota). Dr Burfeind and
colleagues have pointed out that surgical morbidity, mortality, and
long-term survival have been our traditional reported outcome pa-
rameters. However, with multimodality diagnostic and treatment
options now becoming routine in patients with certain diseases, par-
ticularly lung cancer, an ever-increasing amount of time has to be
spent by patients in investigating, treating, and hopefully regaining
their personal health. This has resulted in a growing appreciation
about health-related QOL for these patients. Specifically regarding
our patients with lung cancer, who are indeed oftentimes middle-
age, as you said, or older, it would seem that knowledge of QOL
would provide useful information, in fact, essential information
for the patients, their families, primary care providers, and other spe-
cialists, namely, our referrers. In broad terms, QOL is a concept that
is easy to intuitively grasp but difficult to reliably measure. It’s a dy-
namic concept varying over time. The authors are to be commended
on the prospective nature of this study dating back to 1999, which
involved a large cohort of patients, 422, which to my knowledge
represents the largest number of patients thus reported on. As a cli-
nician, I worry about missing data. Although many of us in the roomThe Journal of Thoaren’t statisticians, I and perhaps others get nervous when 20% to
38% of the data are missing. I would have thought that with a dedi-
cated clinical research assistant administering the questionnaire and
use of a computer that missing data elements could have been less or
caught earlier. If the missing data were due to patients not keeping
their scheduled clinic appointments, is there any process now in
place for avoiding that in the future? Could you please comment
on this 20% to 38% missing data and the validity of imputing data?
Dr Burfeind. As you know, missing data is a common problem
in QOL research, and it’s important because the reason it’s missing
can often be related to a patient’s QOL. That being said, if they don’t
come to the clinic, there are numerous reasons why that may happen.
It may be that their QOL is so poor that they don’t come to the clinic.
Alternatively, in some instances it could be that they’re feeling so
well that they skip a clinic appointment or that they receive part
of their care elsewhere, and at a large referral center, such as
Mayo or Duke, many people will get referrals from elsewhere and
some of the patient’s postoperative care may be assumed closer to
home. I think those are some of the reasons explaining the missing
data. As you may have noticed, it was almost never missing because
of a patient coming to the clinic and then either refusing to take the
survey or us just forgetting to administer it. It was almost always be-
cause the patient didn’t show up in the clinic. As far as the imputa-
tion method, I think we used the most up-to-date method to do that;
that is, it took into effect the patient’s other QOL scores as well as
the preoperative variables that I had said earlier. So we tried to
use all available data to impute rather than either throwing out all
the patients who didn’t have complete data or using the last value
forward or mean value methods. Although no method of imputation
is perfect, we tried to use a method that would introduce the least
amount of bias.
Dr Nichols. My second question relates to the respondents. As
you said, the majority of the respondents were women and 82%
of the respondents were both white and married. Initially, 564 pa-
tients were given the survey and underwent lobectomy. Do you
have any idea howmany patients never participated in the initial sur-
vey process and still underwent lobectomy at Duke, and would their
demographics have altered the characteristics of your cohort?
Dr Burfeind. It’s possible, and that’s certainly a bias. We do not
collect the information prospectively on who decides to participate
and who doesn’t. I do know that we perform approximately 300 an-
atomic lobectomies per year, so that would be approximately one
third of the patients are participating in this study.
Dr Nichols. My final question relates to your conclusion that
QOL domains after lobectomy are similar and usually transient in
these 2 groups, and because the 5-year survival data between the
groups is no different, your data therefore support lobectomy in
the elderly. What I don’t think has been addressed is the clinical de-
cision-making process that qualified these patients for lobectomy in
the first place. I think I, my colleagues, and others here in this room,
with a reasonable degree of comfort, can predict who we can get
through operations and ultimately out of the hospital. What I haven’t
mastered is which patients will have their QOL devastated. Was
there a difference between the 2 groups in terms of operative mortal-
ity, or, for that matter, morbidity, and did this have any relationship
with your preoperative QOL scores?
Dr Burfeind. That’s a very good point, and I think that’s the
most important limitation to this study. This is taking that groupracic and Cardiovascular Surgery c Volume 136, Number 3 603
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through a lobectomy, and, in fact, did get through the lobectomy.
Because you had to take a preoperative and at least 1 postoperative
QOL assessment, that means you survived at least 90 days. I think
what it does say, though, is that in that group of patients who you
think you can get through the operation, their QOL isn’t usually
devastated, on average, or as it would be measured here, but in
fact they will have a transient decrease, but it should come back
to baseline. The more important question that you had was can
we do something to help predict which patients are going to sur-
vive, and I am actually looking at that information now and trying
to see whether baseline QOL can predict 30-day mortality. It has
been shown in some other types of cancer and it may here. It’s
just that I need some more time to make sure it’s not confounded
by things like performance status and forced expiratory volume in
1 second and make sure that it shakes out in a multivariable model
that way.
Dr Nichols. You and your colleagues are to be commended on
trying to move us forward in our quest of furthering our understand-
ing of QOL.
Dr Scott J. Swanson (New York, New York). Obviously I’m go-
ing to ask you one question. Did you look at video-assisted thoracic
surgery as a separate category and did that have any effect? If we’re
going to do one at a time, I’ll have one other question.
Dr Burfeind. Being from Duke, I definitely looked at that. This
dataset was not ideally set up to answer that question. The short an-
swer is there was no difference between QOL in those 2 groups. I
think the main problemwas that by using 3months as your first post-
operative QOL time point, you’re missing the boat. The main advan-
tages to video-assisted thoracic surgery lobectomy may have been
most significant at 1, 2, or 6 weeks, even 2 months. The 3-month
time point was the one that had the most missing data. So it makes
it really hard to draw firm conclusions.
Dr Swanson. The second question, 70 years of age is getting to
be sort of younger for us as we go on here. Did you look at sort of
extreme ages, maybe more than 80 or 85 years, and see if that was
different?
Dr Burfeind. I didn’t, and I think that’s a great point, Scott. I
picked 70 years because it was the median age of patients diagnosed
with lung cancer in the United States. Most previous studies had
used a cutoff of 65 years to describe elderly patients. We’re glad
when somebody is 65 years. That’s one of the young patients. But
I also didn’t keep age as a continuous variable and try to find
some cut point above which QOL seemed to suffer more. I could
go back and do that, but it makes the statistical model quite complex.
So actually I don’t have the answer.
Dr Swanson. Do you know how many patients aged more than
80 years are in that group?604 The Journal of Thoracic and Cardiovascular Surgery c SepDr Burfeind. Seventeen of the 166 patients were 80 years or
older, so the majority of patients in group 2 were between 70 and
80 years.
Dr Michael T. Jaklitsch (Boston, Massachusetts). Thank you
for this study. I think it’s a very important contribution. If for no
other reason, suggesting that whatever nadir there is that may
have separated the 2 groups is resolved by 3 months, that in and
of itself is extremely valuable data. There are 2 other variables
that I would ask you to look at within this dataset. What was the in-
cidence of people going to rehabilitation facilities? In particular, that
3-month mark may be that they have gotten out of rehabilitation and
they’re not quite strong enough to make the trip back down to Dur-
ham. So that becomes an important variable. And then also, because
respiratory reserve declines as a function of age, if you look at which
lobe was taken, you may pick up a signal there on the lower lobes,
because if you take a lower lobe in an 80-year-old patient, that’s
a much bigger hit than if you took the upper lobe.
Dr Burfeind. I agree. I will look at those things. The retrospec-
tive nature of this made it difficult to try and parse out why some-
body didn’t come back to the clinic. You know, if this had been
in a randomized trial and we were very closely monitoring that,
we probably would have called to find out why they didn’t come
back, and that is a very important limitation and a source of impor-
tant bias in this study.
DrThomasW.Rice (Cleveland, Ohio).Age is a continuous var-
iable, and by dichotomizing your data, you’ve lost a lot. So you
would do us a big service by looking at the continuum and telling
us if there is a certain age we should be worried about. And most
of us aren’t concerned about the 70-year-old. We’re concerned
about the 80-year-old. So please do it as a continuous variable.
Dr Burfeind. Thank you, Dr Rice.
Dr Neri M. Cohen (Baltimore, Maryland).What number of pa-
tients go on to get adjuvant therapy? Because that nadir in the 3
months is when the 1B’s and the II’s are going to be in the midst
of their chemotherapy, and I can’t tell you how many times they
come back and tell me at 3 months, ‘‘The surgery was a breeze.
The chemo is killing me.’’
Dr Burfeind. That’s a very good point, and I didn’t look at that.
Dr Douglas E. Wood (Seattle, Washington). I’ll make one other
point about your conclusions. I guess I’ll be even more optimistic
than some of the other discussants and say that your conclusions
said that one can consider resection in selected elderly patients. I
guess I would be even more bold just to say that the default position
would be that we would consider resection in all elderly patients and
that one has to have a compelling reason not to offer it rather than the
other way around.
Dr Burfeind. Thank you, and I think that is the approach we typ-
ically take, exactly.tember 2008
